This is a working overview of growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-27 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
== Mechanotaxis in wound healing == In wound healing, fluid shear stress plays a large role in the mechanotaxis of endothelial cells to the wound site. The inner lining of blood vessels is composed of these endothelial cells, which means that these cells are continuously experiencing fluid shear stress from blood rushing through the vessels. This mechanical stress on the apical side of the endothelial cells leads to integrin signaling, which involves the recruitment of focal adhesion kinase (FAK), Shc, and Crk, and will lead to changes in cell-cell and cell-ECM adhesion. These changes involve lamellipodial protrusions and focal adhesion (FA) formation at the front of the cell, as well as the dismantling of FAs at the rear of the cell, and cause endothelial cells to move in the direction of the flow. Constant laminar flow has been found to improve cell migration in wounds and increases the rate of wound closure.
=== Space exploration === As humans begin venturing into space for a longer time, the nutritional requirements for maintaining crew health is critical. Currently NASA is exploring ways of integrating 3D printing food into space in order to sustain the crew's dietary requirements. The vision is to 3D print powdered food layers that have a shelf life of 30 years instead of using traditional freeze dried food that have a shelf life of 5 years. In addition to dietary requirements, 3D printing food in space could provide a morale boost, as the astronauts would be able to design custom meals that are aesthetically pleasing. In September 2019, Russian cosmonauts, along with Israeli startup Aleph Farms, grew meat from cow cells, then 3D printed the cells into steaks.
=== Liver fatty acid storage === In a high-fat diet-induced obesity model of fatty liver disease (i.e., excessive buildup of fat in the liver), mice fed a diet that increased intestinal levels of SC-FAs showed reductions in their livers' synthesis of lipids, triglyceride levels, and weights. These reductions did not occur in Ffar3 gene knockout mice but did occur in Ffar2 gene knocked-out mice. These results indicate that the SC-FA-induced activation of FFAR3 suppresses the liver's accumulation of fatty acids that underlies the development of fatty liver disease in this mouse model. Other studies have found that Ffar3 gene knockout mice showed less weight gain than wild-type mice under standard laboratory conditions, but this difference was lost in mice reared under germ-free conditions (i.e., which causes the mice to have lower intestinal and tissue levels of SC-FAs). These findings indicated that the activation of FFAR3 but not FFAR2 by SC-FAs protects against developing fatty liver disease in mice.
Sources: en.wikipedia.org
=== Disease-modifying agents === Disease-modifying antirheumatic drugs (DMARDs) are the primary treatment for RA. They are a diverse collection of drugs, grouped by use and convention. They have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. DMARDs should be started early in the disease as they result in disease remission in approximately half of people and improved outcomes overall. The following drugs are considered DMARDs: methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, TNF inhibitors (certolizumab, adalimumab, infliximab and etanercept), abatacept, anakinra, and auranofin. Additionally, rituximab and tocilizumab are monoclonal antibodies and are also DMARDs. Use of tocilizumab is associated with a risk of increased cholesterol levels. The most commonly used agent is methotrexate, with other frequently used agents including sulfasalazine and leflunomide. Leflunomide is effective when used for 6–12 months, with similar effectiveness to methotrexate when used for 2 years. Sulfasalazine also appears to be most effective in the short-term treatment of rheumatoid arthritis. Hydroxychloroquine, in addition to its low toxicity profile, is considered effective for the treatment of moderate RA symptoms. Pharmacokinetic characteristics of Hydroxychloroquine are complex due to the large volume of distribution, significant tissue binding, and long terminal elimination half-life.
== Melamine on metal surfaces == It is reported that melamine molecules adsorbed on gold or silver surface tend to arrange into honeycomb or closed-packed structures. Such a self-assembly occurs due to the inter-molecular hydrogen bond interaction. This ordering was further investigated using classical Monte Carlo and DFT methods.
== Evolutionary implications == Most humans have multiple copies of the regulatory gene sequence for prodynorphin, which is virtually identical among all primates, whereas other primates have only a single copy. In addition, most Asian populations have two copies of the gene sequence for prodynorphin, whereas East Africas, Middle Easterners, and Europeans tend to have three repetitions. The extent of regulatory gene disparities for prodynorphin, between human and primates, has gained the attention of scientists. There are very few genes known to be directly related to mankind's speciation from other great apes. According to computational biologist researcher Matthew W. Hahn of Indiana University, "this is the first documented instance of a neural gene that has had its regulation shaped by natural selection during human origins." The prodynorphin polypeptide is identical in humans and chimpanzees, but the regulatory promoter sequences have been shown to exhibit marked differences. According to Hahn, "humans have the ability to turn on this gene more easily and more intensely than other primates", a reason why regulation of this gene may have been important in the evolution of modern humans' mental capacity.
Sources: en.wikipedia.org
On television, d'Abo played Ta'Ra, an alien medical officer in the science fiction miniseries Something Is Out There (1988), which was followed by a six-episode NBC mini-series of the same name, and she played Anne Summerton in the TV adaptation of Jeffrey Archer's novel Not a Penny More, Not a Penny Less (1990) directed by Clive Donner. D'Abo had a supporting role as a pretentious stained-glass artist in the low-budget British comedy Leon the Pig Farmer (1992). She appeared in the 1994 film The Browning Version and starred in Timelock (1996). D'Abo has had roles in various low-budget, straight-to-video action, horror and fantasy films such as Tomcat: Dangerous Desires (1992), as well as guest roles on television shows Tales from the Crypt (1993), Red Shoe Diaries (1992) and Murder, She Wrote (1992). She reunited with her James Bond director John Glen for a guest-starring role on the television series Space Precinct and for the feature film The Point Men (2001). Glen later said that he cast her in three different projects was because she was one of his favourite actresses. She played the mother of Lara (played by Keira Knightley) in the television miniseries version of Doctor Zhivago (2002), and she was Queen Hecuba in the Emmy-nominated miniseries Helen of Troy (2003). She had a small role in the French film L'Enfer (Hell, 2005), directed by Danis Tanovic whose stars included fellow Bond Girl Carole Bouquet. D'Abo and John Cork wrote the book Bond Girls Are Forever, published in 2002, which is a tribute to the women who have played the role of a Bond girl.
The wool is left to lie in soak for five hours, and then, after carding it, it is thrown in again, until it has fully imbibed the colour. Archaeological data from Tyre indicate that the snails were collected in large vats and left to decompose. This produced a hideous stench that was mentioned by ancient authors. Not much is known about the subsequent steps, and the actual ancient method for mass-producing the two murex dyes has not yet been successfully reconstructed; this special "blackish clotted blood" colour, which was prized above all others, is believed to be achieved by double-dipping the cloth, once in the indigo dye of H. trunculus and once in the purple-red dye of B. brandaris.
=== Fasegram === A Fasegraphy allows expanding the system of Electrocardiography diagnostic features, based on the evaluation of the speed characteristics of the process, and thereby increasing the sensitivity and specificity of ECG-diagnostics. Fasegraphy allows determining the initial features of changes in the cardiac muscle, even on a single-channel ECG, which are underestimated in traditional ECG diagnostics.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.